Article and Video CATEGORIES
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are converging on Chicago for the American Society for Clinical Oncology (ASCO) annual conference, the biggest cancer meeting of the year. There is far too much happening for people to be able to see everything, but fortunately people will be providing summaries on Twitter (follow me at @JackWestMD), various blogs (I'm writing commentary for Medscape), and lots of online and print news outlets. GRACE will be doing an annual "highlights" video series in just a few weeks, but in the meantime, here is a preview of the top 10 presentations in lung cancer from my perspective, primarily thinking about likely impact on clinical practice for thoracic oncology patients:
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…